Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
复制标题
DOI：
10.1111/dom.14143
复制
发表时间：
2020-11
期刊：
影响因子：
--
通讯作者：
Neal B
中科院分区：
文献类型：
--
作者：
Matthews DR;Wysham C;Davies M;Slee A;Alba M;Lee M;Perkovic V;Mahaffey KW;Neal B
本研究比较了卡格列净心血管评估研究（CANVAS）项目中有心血管疾病病史/高风险的2型糖尿病受试者使用卡格列净与安慰剂开始胰岛素和其他抗高血压药物（AHA）的情况。1年后，与安慰剂相比，接受卡格列净治疗的受试者较少开始任何AHA（7% vs. 16%），胰岛素（3% vs. 9%）或任何非胰岛素AHA（5% vs. 12%）（所有P <0.001）;总体AHA启动率随时间推移而增加，但卡格列净组始终低于安慰剂组。在研究期间，接受卡格列净治疗的参与者开始胰岛素治疗的可能性比安慰剂低2.7倍（风险比，0.37; 95% CI：0.31，0.43; P < .001）。卡格列净组和安慰剂组中10%的患者从试验开始接受胰岛素治疗的时间差约为2年。与安慰剂相比，卡格列净组至开始其他AHA（包括二甲双胍、二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂和磺脲类药物）的时间也延迟（各P < .001）。与安慰剂相比，卡格列净延迟了开始其他AHA的需要，并延迟了胰岛素治疗的时间，这一结果对许多糖尿病患者很重要。
This study compared initiation of insulin and other antihyperglycaemic agents (AHAs) with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year, fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs. 16%), insulin (3% vs. 9%) or any non‐insulin AHA (5% vs. 12%) (P < .001 for all); overall AHA initiation rates increased over time but were consistently lower with canagliflozin compared with placebo. During the study, the likelihood of initiating insulin was 2.7 times lower for participants treated with canagliflozin compared with placebo (hazard ratio, 0.37; 95% CI: 0.31, 0.43; P < .001). The time difference between 10% of patients in the canagliflozin and placebo groups being initiated on insulin from the beginning of the trial was about 2 years. Time to initiation of other AHAs, including metformin, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and sulphonylureas, was also delayed for canagliflozin versus placebo (P < .001 for each). Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and delayed time to insulin therapy, an outcome that is important to many people with diabetes.
登录
查看更多内容
DOI：
10.1111/dom.12924
发表时间：
2017-07
期刊：
Diabetes, obesity & metabolism
影响因子：
--
作者：
Neal B;Perkovic V;Mahaffey KW;Fulcher G;Erondu N;Desai M;Shaw W;Law G;Walton MK;Rosenthal N;de Zeeuw D;Matthews DR;CANVAS Program collaborative group
通讯作者：
CANVAS Program collaborative group
影响因子：
16.2
作者：
Cefalu, William T.;Dawes, Daniel E.;Yatvin, Alan L.
通讯作者：
Yatvin, Alan L.
DOI：
10.1111/nyas.12852
发表时间：
2015-01-01
期刊：
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014
影响因子：
--
作者：
Rosenthal, Norm;Meininger, Gary;Demarest, Keith
通讯作者：
Demarest, Keith
影响因子：
1.9
作者：
Lin DY;Dai L;Cheng G;Sailer MO
通讯作者：
Sailer MO
影响因子：
8.8
作者：
Peto R;Pike MC;Armitage P;Breslow NE;Cox DR;Howard SV;Mantel N;McPherson K;Peto J;Smith PG
通讯作者：
Smith PG